Australian Indigenous HealthInfoNet
http://www.healthinfonet.ecu.edu.au

 

What is hepatitis C?

  • Home
    • » Infectious conditions
      • » Hepatitis
        • » Reviews
          • » What is hepatitis C?

{banner}

Introduction

Hepatitis C is a blood-borne viral infection that causes inflammatory liver disease [1]. Globally, an estimated 170 million persons are chronically infected with hepatitis C virus (HCV) and 3 to 4 million persons are newly infected each year [2]. HCV causes acute hepatitis, but only one third of cases are symptomatic, with clinical features similar to other forms of acute viral hepatitis [3]. Approximately three quarters of all people infected with HCV develop chronic infection leading to various degrees of liver disease.

Transmission

Transmission of HCV typically occurs via blood-to-blood contact [1]. Transfusion, shared drug injecting equipment, and needlestick injuries are the most efficient methods for transmitting HCV infection [4]. Injecting drug use (IDU) is the most common method of contracting the virus and is responsible for the vast majority of new notifications. Unsterile tattooing and body piercing procedures also pose a risk for the transmission of HCV, as does the use of unsterile hairdressing equipment (such as razors and clippers) and needlestick injuries among health care workers [1]. In the past, blood transfusions too contributed to levels of infection, but current screening procedures have almost completely eliminated the risk of contracting HCV from a blood transfusion [5]. HCV can be passed from mother to foetus during pregnancy but perinatal transmission is relatively ineffective [4]. Sexual contact cannot be dismissed as a possible route of HCV transmission [4] but the contribution of sexual transmission to overall levels of HCV infection remains controversial [6] [7]. Australian studies indicate that less than 2% of HCV infection is associated with sexual contact [8] [9] cited in [6] and the risk of sexual transmission from a person with chronic HCV infection is probably negligible [10] cited in [4]. Person-to-person transmission in the household setting appears to be extremely uncommon but where the possibility of blood contact exists, toothbrushes, razors or other items should not be shared [4].

Acute HCV infection

Symptoms associated with acute HCV occur in approximately 30% of cases [3]. Symptoms are variable but usually mild, the infected person may develop nausea, right upper abdominal discomfort, malaise, dark urine, light-coloured stools and jaundice [3] [5]. The number of notified incident cases of acute HCV are small because most acute infections do not present with definite symptoms [11]. In the majority of cases, the person remains asymptomatic and develops a chronic infection that may go undetected for years [12].

Between 75% - 80% of all patients infected with HCV develop chronic infection (persisting for more than 6 months) [11] with potentially serious, long term physical and psychological consequences [13].

Chronic HCV infection

Fatigue, lethargy and exhaustion are very common among patients with chronic HCV [11]. Other physical symptoms include nausea, pain and feelings of general malaise [14]. Psychological problems are not uncommon among HCV infected persons [15] and include: depression and mood swings; anxiety; social isolation; low self esteem; the development of mild paranoia; and acute stress [14].

Chronic HCV infection may result in various degrees of liver disease from: minimal damage; to chronic hepatitis (that may be mild, moderate or severe in degree); through to cirrhosis, liver cell cancer and liver failure [11]. People with chronic HCV infection are at increased risk of advanced liver disease if their alcohol consumption is heavy, they are co-infected with HIV or HBV, or have already progressed to moderate-severe hepatic fibrosis [16] cited in [6].

Level of HCV infection

HCV infection became a notifiable disease in all Australian state and territory health jurisdictions in the early 90s [1] [6]. In 2002, an estimated 225,000 Australians were living with hepatitis C infection [17] and up to 20 000 new cases are now notified annually [6] [17]. Much lower numbers of incident HCV cases are reported due to the generally asymptomatic nature of newly acquired HCV infection, inadequate HCV testing and the demands of enhanced HCV surveillance [6].

Risk associated with IDU

Several population groups are clearly at increased risk of HCV infection [6] foremost among them injecting drug users (IDUs). In Australia, current and past injecting drug users comprise the vast majority of infected persons [15]. IDUs continue to have high HCV incidence rates [6] and are at greatest risk for ongoing transmission [15]. More than 75% of newly acquired HCV cases are associated with a recent history of IDU [17].

Recent evidence suggests ongoing and possibly increasing HCV risk among IDUs. Among people seen at needle and syringe programs (NSPs), prevalence of hepatitis C among those injecting for less than three years increased from 17% in 1998 to 38% in 2002 [17]. In addition, the prevalence of IDU has increased with estimates of the number of dependent heroin injectors doubling between 1988 and 1997 [18] cited in [6]. The prevalence of HCV in prison populations is extremely high with studies from Melbourne and Sydney suggesting infection among more than a third of prisoners and approximately two thirds of prisoners reporting a history of injecting drug use [19] [20] cited in [6].

Prevention

The HCV epidemic continues to grow in response to high levels of HCV transmission among IDUs [6]. Given the high prevalence of infection, the sharing of needles and syringes must be virtually eliminated if transmission is to be significantly reduced [21]. No vaccine exists for HCV and prevention of transmission remains the most effective way to avoid infection [4].

Evidence suggests that the distribution of clean needles and syringes reduces the spread of blood-borne diseases. Needle and syringe distribution services, also referred to as needle exchanges, operate in every state of Australia. However, as HCV was endemic among IDUs before the implementation of NSPs, and as the exclusive use of sterile needles and syringes is difficult to ensure, even occasional episodes of shared injecting equipment may be sufficient to sustain high rates of HCV transmission [4]. Calls have been made for a major expansion of strategies for distribution and disposal of needles and syringes to combat current high levels of HCV [21].

References

  1. Burns J, Burrow S, Genovese E, Pumphrey M, Sims E, Thomson N (2003) Other communicable diseases. In: Thomson N, ed. The health of Indigenous Australians. South Melbourne: Oxford University Press: 397-441
  2. National Centre in HIV Epidemiology and Clinical Research (2007) HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2007. Sydney: Australian Institute of Health and Welfare
  3. National Centre in HIV Epidemiology and Clinical Research (2007) Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: surveillance report 2007. Sydney: Australian Institute of Health and Welfare
  4. Australian Institute of Health and Welfare (2007) Statistics on drug use in Australia 2006. Canberra: Australian Institute of Health and Welfare
  5. National Centre in HIV Epidemiology and Clinical Research (2006) HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2006. Darlinghurst, NSW: Australian Institute of Health and Welfare
  6. Schultz R (2005) Hepatitis A outbreak in Central Australia. Northern Territory Disease Control Bulletin; 12(4): 4-7
  7. Clementson C (2005) Contemporary issues in Aboriginal and Torres Strait Islander health: HIV, hepatitis and sexual health. Darlinghurst, NSW: Australasian Society for HIV Medicine
  8. McCaughan GW, Torzillo PJ (2000) Hepatitis A, liver transplants and Indigenous communities [editorial]. Medical Journal of Australia; 172: 6-7
  9. MacIntyre CR, Burgess M, Isaacs D, MacIntyre PB, Menzies R, Hull B (2007) Epidemiology of severe Hepatitis A in Indigenous Australian children. Journal of Paediatrics and Child Health; 43(5): 383-387
  10. Hanna JN, Hills SL, Humphreys JL (2004) Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Medical Journal of Australia; 181(9): 482-485
  11. Schizophrenia Fellowship of NSW Inc (2005) Aboriginal and Torres Strait Islander people. Retrieved from http://www.sfnsw.org.au/Quality-of-Life/Indigenous/QoL-Indigenous/default.aspx
  12. Hanna JN, Warnock TH, Shepherd RW, Selvey LA (2000) Fulminant hepatitis A in Indigenous children in north Queensland. Medical Journal of Australia; 172: 19-21
  13. National Centre in HIV Epidemiology and Clinical Research, Australian Institute of Health and Welfare (2005) HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2005. Sydney: National Centre in HIV Epidemiology and Clinical Research and the Australian Institute of Health and Welfare
  14. Merritt A, Symons D, Griffiths M (1999) The epidemiology of acute hepatitis A in north Queensland, 1996-1997. Communicable Diseases Intelligence; 23(5): 120-124
  15. Barrett EJ (1976) Hepatitis B in Australian Aborigines and Torres Strait Islanders: geographical, age and familial distribution of antigen subtypes and antibody. Australian and New Zealand Journal of Medicine; 6(2): 106-11
  16. Wood N, Backhouse L, Gidding HF, Gilbert GL, Lum G, McIntyre PB (2005) Estimates of chronic hepatitis B virus infection in the Northern Territory. Communicable Diseases Intelligence; 29(3): 289-290
  17. Kaldor J, Plant A, Thompson S, Longbottom H, Rowbottom J (1996) The incidence of hepatitis B infection in Australia: an epidemiological review. Medical Journal of Australia; 165(6): 322-326
  18. MedlinePlus (2008) Hepatitis B. Retrieved 29 January 2009 from http://www.nlm.nih.gov/medlineplus/ency/article/000279.htm
  19. Sullivan JS, Hanna JN (1999) A genetic marker associated with non-response to recombinant hepatitis B vaccine by indigenous Australian children [letter]. Journal of Paediatrics and Child Health; 35(4): 412-3
  20. Hanna J, Faoagali J, Buda P, Sheridan J (1997) Further observations on the immune response to recombinant hepatitis B vaccine after administration to Aboriginal and Torres Strait Island children. Journal of Paediatrics and Child Health; 33(1): 67-70
  21. MedlinePlus (2008) Hepatitis C. Retrieved 29 January 2009 from http://www.nlm.nih.gov/medlineplus/ency/article/000284.htm

© Australian Indigenous HealthInfoNet 2013 
This product, excluding the Australian Indigenous HealthInfoNet logo, artwork, and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY-NC-ND 3.0 (CC BY-NC-ND 3.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures.

 
© 2001-2014 Australian Indigenous HealthInfoNet